

CIF A-18.758.300  
Avda. de la Innovación, n 1  
Edificio BIC (Ofic. 211)  
P. T. de Ciencias de la Salud  
18100 Armilla (Granada)  
**Tel: 958 750 598**

Mercado Alternativo Bursátil  
Plaza de la Lealtad, 1  
28014 Madrid

In Granada, 29 December 2014

## RELEVANT FACT OF NEURON BIO

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB the company, Neuron Bio, S.A. (hereinafter "NEURON BIO" or the "Company"), hereby puts in knowledge the following information.

The European Patent Office (EPO) has issued the patent "**Neuroprotective, hypocholesterolemic and antiepileptic compound**" to Neuron Bio on 24 December 2014, published in the Spanish Official Bulletin of Industrial Property with number EP2245151 B. The patent protects the new chemical entity NST0037 and its use for the prevention and treatment of neurodegenerative diseases, cognitive impairment and pathological processes linked to age.

This is the second patent granted to NEURON BIO by the European Patent Office and could allow the Company to achieve commercial agreements with third parties on the molecule for its use in such severe pathologies as the Alzheimer's disease, which has no cure to date.

Press release is attached.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate  
Chairman of the Board of Directors

---

**Press Release**

---

**Neuron Bio achieves the European patent of a new compound against the Alzheimer's**

- **The patented compound may be the key to the prevention and treatment for Alzheimer's disease and other neurodegenerative diseases**
- **Thanks to this patent the Spanish biotech company expects to achieve important commercial agreements in coming years**

Granada, 29 December 2014

The European Patent Office (EPO) has issued the patent "Neuroprotective, hypocholesterolemic and antiepileptic compound" to Neuron Bio on 24 December in order to protect its new compound NST0037, the most advanced of the Spanish biotech company against the Alzheimer's disease so far.

The compound NST0037 has been developed by Neuron Bio from its projects regarding the search of neuroprotective statins that began in January 2007. The patent application was filed in October 2009 and finally it has been recently granted by the European Patent Office.

This is one of the most important achievements of the Spanish biotech company for its research activity in the Alzheimer's prevention, in which the company is an international reference.

The patented compound is a new chemical entity derived from the simvastatin that offers improved effects to prevent neurodegenerative processes related to the Alzheimer's disease and other neurodegenerative diseases associated with the age and with no cure currently. It might also be useful to treat different pathologies of the central nervous system such as Parkinson's disease and Huntington's disease.

Fernando Valdivieso, Chairman of the company has evaluated very positively this new "the recent awarded patent is the key to future of Neuron Bio, because it will allow us to move forward the achievement of commercial agreements with pharmaceutical companies interested in the development of molecules with new action mechanisms for the creation of more effective drugs in the fight against the Alzheimer's."

This patent is an addition and complements the patent granted by the same office the last 30 October 2014 that protect the use of simvastatin as an antiepileptic. So, it is the second European patent achieved by Neuron Bio in its main activity of R&D.